Company news
Immuneering Corporation news in 2023
Immuneering Corporation's news releases, calls and decks from 2023, newest first.
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
December 11, 2023
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 8, 2023
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
October 11, 2023
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 3, 2023
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 2, 2023
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
June 4, 2023
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
May 3, 2023
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
April 17, 2023
Immuneering Announces $30 Million Underwritten Offering
April 17, 2023
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
March 27, 2023
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 5, 2023
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 26, 2023
Calls in 2023
Decks in 2023
- Investor Presentation (April 2023)
Investor deck · 47 slides · Apr 18, 2023
- Investor Presentation (March 2023)
Investor deck · 39 slides · Mar 6, 2023